NCT03161002

Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 400 (estimated)
• Sponsor: Cui Yimin · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%. Ticagrelor is a new-type receptor antagonist of P2Y12 and it is not affected by the influence of CYP2C19 polymorphism. With lack of predicted biomarkers, especially the research data of Chinese, it has the important significance in studying individual differences of ticagrelor in the antiplatelet efficacy and safety, through the pharmacogenomics research. The aim of this study is to determine the polymorphism of drug metabolizing enzymes, drug transporters and drug target genes in Chinese population. By detecting the gene polymorphism, we intend to study the pharmacokinetic/ pharmacodynamics/ pharmacogenomics (PK-PD-PG) correlation of ticagrelor and provide scientific basis for accurate medication guide for people to use ticagrelor.

Conditions

• Ticagrelor
• Pharmacokinetics
• Pharmacodynamics
• Pharmacogenomics
• Accurate Medication

Interventions

Type	Name	Description
GENETIC	detection of genotype	detection of genotype by next generation sequencing

Timeline

• Start date: 2017-05-31
• Primary completion: 2021-10-01
• Completion: 2021-12-01
• First posted: 2017-05-19
• Last updated: 2020-12-22

Locations

7 sites across 1 country: China